Phathom PHARMACEUTICALS

CORPORATE OVERVIEW
April 2022

CHANGING THE LANDSCAPE IN GI
Going beyond to advance treatments for acid-related disorders

We are building a leading gastrointestinal-focused pharmaceutical company to improve the lives of people suffering from GI diseases.

Phathom is developing vonoprazan, an investigational potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to be the first gastric, anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.

Our development programs build upon a solid foundation of studies in over 8,000 patients around the world. Vonoprazan* is currently approved in Japan and numerous other countries in Asia and Latin America.

Quick Facts

>80 Employees

Founded May 12, 2019

IPO October 29, 2019

$PHAT on NASDAQ

ABOUT US

Phathom Pharmaceuticals, Inc.

100 Campus Drive | Florham Park, NJ 07932

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We are a team of highly driven pharmaceutical professionals who are passionate about our mission to improve the lives of people suffering from gastrointestinal diseases.

OUR LOCATIONS

Florham Park, NJ
- Corporate Headquarters
- 20 miles from NYC

Buffalo Grove, IL
- R&D Headquarters
- 25 miles from Chicago

LEADERSHIP TEAM

Terrie Curran
Chief Executive Officer

Azmi Nabulsi, M.D., M.P.H.
Chief Operating Officer

Martin Gilligan
Chief Commercial Officer

Tom Harris
Chief Development Sciences Officer

Joe Hand
Chief Administrative Officer

Molly Henderson
Chief Financial and Business Officer

Eckhard Leifke, M.D., PhD
Chief Medical Officer

Larry Miller
General Counsel

OUR VALUES

Phathom's core values determine our PHATE

P Perseverance	With **hard work** and **determination** we overcome all obstacles
H Humble	We **put others first**, remain grounded, and let our work speak for itself
A Accountable	We are **reliable** and take **personal responsibility** in all that we do
T Transparent	We say what we mean and have **no hidden agendas**.
E Entrepreneurial	We are numble, agile, and **embrace innovation**.

OUR PIPELINE

CLINICAL TRIALS†	TARGET INDICATIONS	PHASE 1[1]	PHASE 2[1]	PHASE 3
Vonoprazan + antibiotics — pHalcon hp	***H. pylori* treatment** Dual therapy (vonoprazan + amoxicillin)			
	Triple therapy (vonoprazan + amoxicillin + clarithromycin)			
Vonoprazan — pHalcon ee	**GERD/EE treatment** Healing of EE and relief of heartburn			
	Maintenance of healing of EE and relief of heartburn			
Vonoprazan — pHalcon nerd	**GERD/NERD treatment** On-demand treatment of heartburn associated with Non-erosive Reflux Disease (NERD)			
	Daily dosing treatment of heartburn associated with NERD			

* Vonoprazan is a product candidate that is under clinical study and that has not been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of vonoprazan.

Phathom
PHARMACEUTICALS

PREVALENCE AND BURDEN OF ACID-RELATED DISORDERS REMAINS HIGH

GERD
(Gastroesophogeal Reflux Disease)

GERD is a common, chronic, recurring condition caused by the exposure of gastric acid from the stomach to the esophagus.

Over 65 million US patients are living with GERD and it is estimated that approximately 2/3 of this population have NERD.

GERD patients with persistent symptoms typically undergo endoscopy and are diagnosed with having either erosive esophagitis (EE) or non-erosive reflux disease (NERD).

Inadequate acid suppression can lead to poor mucosal healing and serious long-term effects. Acid suppression plays an important role in optimizing GERD treatment.

H. pylori
(Helicobacter pylori Infection)

H. pylori is a common cause of chronic stomach lining infection. The bacterium infects ~50% of the world and 36% of the US population.

Chronic inflammation produced by *H. pylori* infection, causes patients to develop a range of pathologies including peptic ulcer disease and gastric cancer.

Studies found that ~1 in 4 patients treated for *H. pylori* will fail first line therapy when using standard clarithromycin triple therapy.

Treatment is recommended for all patients diagnosed with *H. pylori* infection. Anti-secretory agents reduce gastric acid level to increase antibiotic stability and potency against *H. pylori.*



HISTORY OF GASTRIC ACID SUPPRESSION DRUGS

1970s	1980s	25 Years	2000s: Introduced in Asia
H2 Antagonists	Proton Pump Inhibitors	*No new drug classes introduced*	Potassium-Competitive Acid Blockers
			Differentiated MOA